Prosecution Insights
Last updated: August 16, 2026

Acceleron Pharma Inc.

8 pending office actions • 5 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

8
Total Pending OAs
8
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Due ≤ 30 days (2)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (25%)
3
Medium (38%)
3
Easy (38%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (12%)
§112 only1 (12%)
Double-patenting only2 (25%)
Double-patenting + other2 (25%)
Multi-statute (no §101)2 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
75% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
2
Business / Other
25% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BERHANE, SELAM 2 59.0% +55.8%
CHANDRA, GYAN 1 71.3% +27.4%
SZPERKA, MICHAEL EDWARD 1 62.7% +36.9%
D' AMBROSIO, THEA 1 55.8% +56.5%
HADDAD, MAHER M 1 50.5% +53.9%
MIKNIS, ZACHARY J 1 68.3% +32.5%
HOWARD, ZACHARY C 1 63.8% +38.0%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18010888 ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE HOWARD, ZACHARY C 26d
18328410 TREATMENTS FOR HERMANSKY-PUDLAK SYNDROME BERHANE, SELAM 70d

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18011261 ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) MIKNIS, ZACHARY J 21d
18010888 ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE HOWARD, ZACHARY C 26d
18328410 TREATMENTS FOR HERMANSKY-PUDLAK SYNDROME BERHANE, SELAM 70d
18443985 METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS CHANDRA, GYAN
18683894 COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS SZPERKA, MICHAEL EDWARD
18280899 ACTRII PROTEINS AND USES THEREOF D' AMBROSIO, THEA
18549461 ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE HADDAD, MAHER M
18549474 ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE BERHANE, SELAM

Top Art Units

Art UnitApps
1675 2
1654 1
1641 1
1658 1
1674 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18443985 METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS CHANDRA, GYAN DP Non-Final OA Pending Feb 16, 2024
18683894 COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS SZPERKA, MICHAEL EDWARD §102§103DP Non-Final OA Pending Feb 15, 2024
18280899 ACTRII PROTEINS AND USES THEREOF D' AMBROSIO, THEA 1654 §103 Non-Final OA Pending Sep 07, 2023
18549461 ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE HADDAD, MAHER M 1641 §102§103§112DP Non-Final OA Pending Sep 07, 2023
18549474 ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE BERHANE, SELAM 1675 DP Non-Final OA Pending Sep 07, 2023
18328410 TREATMENTS FOR HERMANSKY-PUDLAK SYNDROME BERHANE, SELAM 1675 §103§112 Non-Final OA 70d Pending Jun 02, 2023
18011261 ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) MIKNIS, ZACHARY J 1658 §112 Non-Final OA 21d Pending Dec 19, 2022
18010888 ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE HOWARD, ZACHARY C 1674 §102§103§112 Non-Final OA 26d Pending Dec 16, 2022

Managing Acceleron Pharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month